Key highlights of the announcement include:
- Elimination of Future Dilution: The Company will no longer be required to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of the Company—substantially diluting existing shareholders.
- No Liability: Neither Klotho nor SkyBell will incur any liability as a result of the termination.
- Refocused Strategy: The termination enables Klotho to remain focused on its core assets and to allocate resources and capital toward advancing its primary therapeutic and longevity programs. These include pipeline candidates targeting neurodegenerative and other age-related diseases.
Today announced that on June 13, 2025, it entered into a Termination and Release Agreement with SkyBell Technologies, Inc. (“SkyBell”), formally ending the Share Exchange Agreement previously executed on March 26, 2025.
“Terminating this agreement allows us to remain focused and build shareholder value while fully concentrating on our core R&D programs,” said Dr. Joseph Sinkule, CEO of KLTO. “We remain committed to delivering transformative therapies for aging and age-related diseases. We believe that anti-aging gene and biologic therapies can be developed to slow the aging process and ultimately reduce mortality caused by age-related organ failure. We are not far from reaching our strategic milestones toward enabling longer, healthier human lifespans.”
